New Insights Into Neurogenic Orthostatic Hypotension

Typical Non-neurologic Causes of Orthostatic Hypotension

Primary Causes of Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension Clinical Phenotypes

Neurotransmitter Disorders

Differences Between nOH and Non-neurogenic OH

Nocturnal Hypertension is a Common Problem in nOH Patient Populations

Pronounced Blood Pressure Variability

Factors That Exacerbate OH and nOH

Concerns and Comorbidities in nOH Patients, Particularly With Advanced Disease

Common Treatment Options for nOH

Droxidopa vs Levodopa

Pivotal Study 301 Key Inclusion and Exclusion Criteria

Orthostatic Hypotension Questionnaire (OHQ)

Study Design Droxidopa Pivotal Trial 301

Study 301 OHQ Composite After 1 Week

Dizziness/Lightheadedness (Item 1 on the Questionnaire)

Study 301 (cont) Increase in Standing BP

Doxidropa Study in Parkinson’s Disease Inclusion and Exclusion Criteria

Study Design

Study 306 in Patients With PD and nOH: Primary Outcome Measure: Dizziness/Lightheadedness

Increases in Standing Blood Pressure

Cardiovascular Disorders in Droxidopa Studies

Evaluation of Deaths in Droxidopa Studies (Including Long-term Safety Extensions)

Rates of Nonfatal Cardiovascular Serious Events Across All Studies

Falls Related to Doxidropa vs Placebo

Droxidopa Clinical Management of Supine Hypertension

Key Points in Using Droxidopa* for Neurogenic Hypotension

Abbreviations

References

References (cont)